Comparison of the efficacy of ciclesonide with that of budesonide in mild to moderate asthma patients after step-down therapy: A randomised parallel-group study

Kuo Chin Chiu; Yen Li Chou; Jeng Yuan Hsu; Ming Shian Lin; Ching Hsiung Lin; Pai-Chien Chou; Chun Liang Chou; Chun Hua Wang; Han-Ping Kuo

doi:10.1038/npjpcrm.2014.10

Comparison of the efficacy of ciclesonide with that of budesonide in mild to moderate asthma patients after step-down therapy: A randomised parallel-group study

Kuo Chin Chiu, Yen Li Chou, Jeng Yuan Hsu, Ming Shian Lin, Ching Hsiung Lin, Pai-Chien Chou, Chun Liang Chou, Chun Hua Wang^*, Han-Ping Kuo

^*Corresponding author for this work

School of Medicine

Research output: Contribution to journal › Journal Article › peer-review

9 Scopus citations

Abstract

BACKGROUND: Inhaled corticosteroids (ICSs) are widely used in asthma control. Ciclesonide (CIC) is an ICS with on-site lung activation for potent anti-inflammatory activity. AIMS: This study aimed to compare the clinical benefit of CIC with budesonide (BUD) in step-down therapy. METHODS: A total of 150 patients with mild-to-moderate asthma well controlled by a combination of ICS and long-acting β₂-agonist were randomised to receive either CIC 320 μg (n = 75) once daily or 2 inhalations of BUD 200 μg (n = 75) twice daily for 12 weeks. The forced expiratory volume in 1 s (FEV₁), maximum mid-expiratory flow (MMEF) and asthma control test (ACT) scores were measured. Ranked stratification of patients and physicians was assessed. RESULTS: Drug adherence was significantly higher in the CIC group than in the BUD group (76.0% vs. 58.7%, P = 0.03). The FEV₁ and MMEF remained stable throughout the 12-week CIC treatment. In the BUD group, FEV₁ significantly decreased at weeks 4 and 12. MMEF had a higher value in the CIC group than in the BUD group. Both patients and physicians ranked CIC over BUD. CONCLUSIONS: CIC is more effective and has better drug adherence than BUD as step-down treatment when asthma is well controlled by combination therapy.

Original language	English
Article number	14010
Journal	npj Primary Care Respiratory Medicine
Volume	24
DOIs	https://doi.org/10.1038/npjpcrm.2014.10
State	Published - 20 05 2014

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/npjpcrm.2014.10

Cite this

Chiu, K. C., Chou, Y. L., Hsu, J. Y., Lin, M. S., Lin, C. H., Chou, P.-C., Chou, C. L., Wang, C. H., & Kuo, H.-P. (2014). Comparison of the efficacy of ciclesonide with that of budesonide in mild to moderate asthma patients after step-down therapy: A randomised parallel-group study. npj Primary Care Respiratory Medicine, 24, Article 14010. https://doi.org/10.1038/npjpcrm.2014.10

@article{a6cbbfa0e1fa4ab7ad13f6e375c43978,

title = "Comparison of the efficacy of ciclesonide with that of budesonide in mild to moderate asthma patients after step-down therapy: A randomised parallel-group study",

abstract = "BACKGROUND: Inhaled corticosteroids (ICSs) are widely used in asthma control. Ciclesonide (CIC) is an ICS with on-site lung activation for potent anti-inflammatory activity. AIMS: This study aimed to compare the clinical benefit of CIC with budesonide (BUD) in step-down therapy. METHODS: A total of 150 patients with mild-to-moderate asthma well controlled by a combination of ICS and long-acting β2-agonist were randomised to receive either CIC 320 μg (n = 75) once daily or 2 inhalations of BUD 200 μg (n = 75) twice daily for 12 weeks. The forced expiratory volume in 1 s (FEV1), maximum mid-expiratory flow (MMEF) and asthma control test (ACT) scores were measured. Ranked stratification of patients and physicians was assessed. RESULTS: Drug adherence was significantly higher in the CIC group than in the BUD group (76.0% vs. 58.7%, P = 0.03). The FEV1 and MMEF remained stable throughout the 12-week CIC treatment. In the BUD group, FEV1 significantly decreased at weeks 4 and 12. MMEF had a higher value in the CIC group than in the BUD group. Both patients and physicians ranked CIC over BUD. CONCLUSIONS: CIC is more effective and has better drug adherence than BUD as step-down treatment when asthma is well controlled by combination therapy.",

author = "Chiu, {Kuo Chin} and Chou, {Yen Li} and Hsu, {Jeng Yuan} and Lin, {Ming Shian} and Lin, {Ching Hsiung} and Pai-Chien Chou and Chou, {Chun Liang} and Wang, {Chun Hua} and Han-Ping Kuo",

year = "2014",

month = may,

day = "20",

doi = "10.1038/npjpcrm.2014.10",

language = "英语",

volume = "24",

journal = "npj Primary Care Respiratory Medicine",

issn = "2055-1010",

}

TY - JOUR

T1 - Comparison of the efficacy of ciclesonide with that of budesonide in mild to moderate asthma patients after step-down therapy

T2 - A randomised parallel-group study

AU - Chiu, Kuo Chin

AU - Chou, Yen Li

AU - Hsu, Jeng Yuan

AU - Lin, Ming Shian

AU - Lin, Ching Hsiung

AU - Chou, Pai-Chien

AU - Chou, Chun Liang

AU - Wang, Chun Hua

AU - Kuo, Han-Ping

PY - 2014/5/20

Y1 - 2014/5/20

N2 - BACKGROUND: Inhaled corticosteroids (ICSs) are widely used in asthma control. Ciclesonide (CIC) is an ICS with on-site lung activation for potent anti-inflammatory activity. AIMS: This study aimed to compare the clinical benefit of CIC with budesonide (BUD) in step-down therapy. METHODS: A total of 150 patients with mild-to-moderate asthma well controlled by a combination of ICS and long-acting β2-agonist were randomised to receive either CIC 320 μg (n = 75) once daily or 2 inhalations of BUD 200 μg (n = 75) twice daily for 12 weeks. The forced expiratory volume in 1 s (FEV1), maximum mid-expiratory flow (MMEF) and asthma control test (ACT) scores were measured. Ranked stratification of patients and physicians was assessed. RESULTS: Drug adherence was significantly higher in the CIC group than in the BUD group (76.0% vs. 58.7%, P = 0.03). The FEV1 and MMEF remained stable throughout the 12-week CIC treatment. In the BUD group, FEV1 significantly decreased at weeks 4 and 12. MMEF had a higher value in the CIC group than in the BUD group. Both patients and physicians ranked CIC over BUD. CONCLUSIONS: CIC is more effective and has better drug adherence than BUD as step-down treatment when asthma is well controlled by combination therapy.

AB - BACKGROUND: Inhaled corticosteroids (ICSs) are widely used in asthma control. Ciclesonide (CIC) is an ICS with on-site lung activation for potent anti-inflammatory activity. AIMS: This study aimed to compare the clinical benefit of CIC with budesonide (BUD) in step-down therapy. METHODS: A total of 150 patients with mild-to-moderate asthma well controlled by a combination of ICS and long-acting β2-agonist were randomised to receive either CIC 320 μg (n = 75) once daily or 2 inhalations of BUD 200 μg (n = 75) twice daily for 12 weeks. The forced expiratory volume in 1 s (FEV1), maximum mid-expiratory flow (MMEF) and asthma control test (ACT) scores were measured. Ranked stratification of patients and physicians was assessed. RESULTS: Drug adherence was significantly higher in the CIC group than in the BUD group (76.0% vs. 58.7%, P = 0.03). The FEV1 and MMEF remained stable throughout the 12-week CIC treatment. In the BUD group, FEV1 significantly decreased at weeks 4 and 12. MMEF had a higher value in the CIC group than in the BUD group. Both patients and physicians ranked CIC over BUD. CONCLUSIONS: CIC is more effective and has better drug adherence than BUD as step-down treatment when asthma is well controlled by combination therapy.

UR - http://www.scopus.com/inward/record.url?scp=84904396631&partnerID=8YFLogxK

U2 - 10.1038/npjpcrm.2014.10

DO - 10.1038/npjpcrm.2014.10

M3 - 文章

C2 - 24841163

AN - SCOPUS:84904396631

SN - 2055-1010

VL - 24

JO - npj Primary Care Respiratory Medicine

JF - npj Primary Care Respiratory Medicine

M1 - 14010

ER -

Comparison of the efficacy of ciclesonide with that of budesonide in mild to moderate asthma patients after step-down therapy: A randomised parallel-group study

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this